PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)

類似資料

• P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]
  著者:: A. Vannucchi, 等
  出版事項: (2022-06-01)
• PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
  著者:: Lucia Masarova, 等
  出版事項: (2023-08-01)
• Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
  著者:: Jean-Jacques Kiladjian, 等
  出版事項: (2023-11-01)
• Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
  著者:: Ruben Mesa, 等
  出版事項: (2023-06-01)
• Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
  著者:: Stephen T. Oh, 等
  出版事項: (2024-02-01)